albendazole has been researched along with Absence Seizure in 78 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Children with persistent neurocysticercosis were randomized into 3 groups-albendazole (n = 19), albendazole and praziquantel (n = 21), and placebo (n = 20)-for 30 days and followed up at 3 and 6 months for resolution and recurrence of seizures." | 9.51 | Efficacy of Combination Therapy of Albendazole and Praziquantel vs Albendazole Monotherapy in Children With Persistent Neurocysticercosis: A Randomized Controlled Trial. ( Khandelwal, N; Saini, AG; Singh, K; Singhi, P, 2022) |
| "There is a paucity of literature to support 14-days albendazole therapy for neurocysticercosis (NCC)." | 9.51 | Fourteen Days vs 28 Days of Albendazole Therapy for Neurocysticercosis in Children: An Open Label Randomized Controlled Trial. ( Dabla, S; Kaushik, JS; Lekhwani, S; Singla, A; Vaswani, ND, 2022) |
| "Albendazole treatment is associated with a possible reduction in focal seizures in the short term (3-6 months), perhaps by hastening the resolution of the cysts." | 9.30 | Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis. ( Carpio, A; Chang, M; Hauser, WA; Jaramillo, A; Kelvin, EA; Romo, ML; Zhang, H, 2019) |
| "In this trial, 178 patients with active or transitional neurocysticercosis cysts and new-onset symptoms were randomized to 8 days of treatment with albendazole (n=88) or placebo (n=90), both with prednisone, and followed for 24 months." | 9.20 | The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis. ( Andrews, H; Bagiella, E; Carpio, A; Hauser, WA; Kelvin, EA; Leslie, D; Romo, ML; Wyka, K, 2015) |
| "Albendazole therapy has been found effective in solitary cysticercus granuloma." | 9.16 | Three-day versus 15-day course of albendazole therapy in solitary cysticercus granuloma: an open label randomized trial. ( Garg, RK; Khurana, N; Malhotra, HS; Shukla, R; Singh, MK; Verma, R, 2012) |
| "To evaluate the efficacy and safety of a combination of albendazole and praziquantel in children with seizures and single small enhancing computerized tomographic lesions." | 9.14 | Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. ( Kaur, S; Khandelwal, N; Singhi, P; Singhi, S, 2009) |
| "The aim of this trial was to evaluate the effects of albendazole (ALB) on cyst disappearance, reduction of the number of cysts and seizure recurrence." | 9.13 | Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. ( Andrews, H; Bagiella, E; Carpio, A; Hauser, WA; Kelvin, EA; Leon, P; Leslie, D, 2008) |
| "To evaluate the response to albendazole treatment in patients who had SSECTL and new onset seizures treated with antiepileptic drugs (AED) in a prospective clinical trial." | 9.13 | Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. ( Chattopadhyay, A; Khandelwal, N; Sawhney, IM; Thussu, A, 2008) |
| "Albendazole plus dexamethasone increased complete or partial resolution of lesions and reduced the risk of subsequent recurrence of seizures among children with neurocysticercosis who had with seizures and 1 or 2 ring-enhancing lesions on computed tomography." | 9.10 | Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. ( Dua, T; Kalra, V; Kumar, V, 2003) |
| "To evaluate the efficacy of albendazole in cases of focal seizures with SSECTLs." | 9.08 | Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial. ( Baranwal, AK; Khandelwal, N; Singhi, PD; Singhi, SC, 1998) |
| "We treated 11 patients with a persistent (> 3 months), solitary small cysticercus granuloma and seizures with albendazole in a daily dose of 15 mg/kg body weight for 14 days." | 9.07 | Albendazole therapy for persistent, solitary cysticercus granulomas in patients with seizures. ( Rajshekhar, V, 1993) |
| "A recent trial suggested that albendazole reduces seizures in adults with neurocysticercosis." | 8.84 | Does albendazole affect seizure remission and computed tomography response in children with neurocysticercosis? A Systematic review and meta-analysis. ( Mazumdar, M; Pandharipande, P; Poduri, A, 2007) |
| "Albendazole is now used for therapy of neurocysticercosis; however, duration of treatment has usually been empirically determined." | 7.67 | Short course of albendazole therapy for neurocysticercosis. ( Del Brutto, OH; Escobedo, F; Penagos, P; Sotelo, J, 1988) |
| "Twenty-three patients had seizure recurrence while on antiepilepsy drugs: 36." | 6.71 | Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis. ( Jain, V; Khandelwal, N; Singhi, P, 2004) |
| "Seizures were present in 94." | 6.69 | Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. ( Khandelwal, N; Ray, M; Singhi, P; Singhi, S, 2000) |
| "55%; P = 0." | 6.43 | Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. ( Coffey, CS; Del Brutto, OH; García, HH; Roos, KL, 2006) |
| "Albendazole treatment leads to a remarkable reduction in neurocysticercosis lesions throughout the body." | 5.91 | Value of whole-body MRI for the assessment of response to albendazole in disseminated neurocysticercosis: a prospective follow-up study. ( Garg, RK; Jain, A; Kumar, N; Malhotra, HS; Malhotra, KP; Pandey, S; Parihar, A; Rizvi, I; Sharma, PK; Uniyal, R; Verma, R; Wangda, K, 2023) |
| "Cysticercosis is a neglected tropical disease set as health priority by WHO." | 5.56 | [Disseminated cysticercosis affecting the brain, the eye and the skin on a Senegalese patient]. ( Diallo, K; Diallo, M; Dione, MAD; Diop, A; Manga, NM; Wembulua, BS, 2020) |
| "Children with persistent neurocysticercosis were randomized into 3 groups-albendazole (n = 19), albendazole and praziquantel (n = 21), and placebo (n = 20)-for 30 days and followed up at 3 and 6 months for resolution and recurrence of seizures." | 5.51 | Efficacy of Combination Therapy of Albendazole and Praziquantel vs Albendazole Monotherapy in Children With Persistent Neurocysticercosis: A Randomized Controlled Trial. ( Khandelwal, N; Saini, AG; Singh, K; Singhi, P, 2022) |
| "There is a paucity of literature to support 14-days albendazole therapy for neurocysticercosis (NCC)." | 5.51 | Fourteen Days vs 28 Days of Albendazole Therapy for Neurocysticercosis in Children: An Open Label Randomized Controlled Trial. ( Dabla, S; Kaushik, JS; Lekhwani, S; Singla, A; Vaswani, ND, 2022) |
| "Seizures are the primary clinical manifestation which could be acute (secondary to active lesions) or remote symptomatic (due to calcified lesions)." | 5.40 | Seizure and radiological outcomes in children with solitary cysticercous granulomas with and without albendazole therapy: a retrospective case record analysis. ( Chakrabarty, B; Gulati, S; Gupta, AK; Jain, P; Kumar, A; Pandey, RM; Sachan, D, 2014) |
| "Albendazole treatment is associated with a possible reduction in focal seizures in the short term (3-6 months), perhaps by hastening the resolution of the cysts." | 5.30 | Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis. ( Carpio, A; Chang, M; Hauser, WA; Jaramillo, A; Kelvin, EA; Romo, ML; Zhang, H, 2019) |
| "In this trial, 178 patients with active or transitional neurocysticercosis cysts and new-onset symptoms were randomized to 8 days of treatment with albendazole (n=88) or placebo (n=90), both with prednisone, and followed for 24 months." | 5.20 | The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis. ( Andrews, H; Bagiella, E; Carpio, A; Hauser, WA; Kelvin, EA; Leslie, D; Romo, ML; Wyka, K, 2015) |
| "Albendazole therapy has been found effective in solitary cysticercus granuloma." | 5.16 | Three-day versus 15-day course of albendazole therapy in solitary cysticercus granuloma: an open label randomized trial. ( Garg, RK; Khurana, N; Malhotra, HS; Shukla, R; Singh, MK; Verma, R, 2012) |
| "We randomized 123 patients with SCC and new-onset seizures to treatment with albendazole plus antiepileptics (treatment), or antiepileptics only (control), and performed magnetic resonance imaging (MRI) scans at 0, 3, 6, 12, and 24 months." | 5.15 | Perilesional gliosis around solitary cerebral parenchymal cysticerci and long-term seizure outcome: a prospective study using serial magnetization transfer imaging. ( de Souza, A; Kovoor, JM; Nalini, A; Siddalingaiah, HS; Thennarasu, K; Yeshraj, G, 2011) |
| "To evaluate the efficacy and safety of a combination of albendazole and praziquantel in children with seizures and single small enhancing computerized tomographic lesions." | 5.14 | Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. ( Kaur, S; Khandelwal, N; Singhi, P; Singhi, S, 2009) |
| "The aim of this trial was to evaluate the effects of albendazole (ALB) on cyst disappearance, reduction of the number of cysts and seizure recurrence." | 5.13 | Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. ( Andrews, H; Bagiella, E; Carpio, A; Hauser, WA; Kelvin, EA; Leon, P; Leslie, D, 2008) |
| "To evaluate the response to albendazole treatment in patients who had SSECTL and new onset seizures treated with antiepileptic drugs (AED) in a prospective clinical trial." | 5.13 | Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. ( Chattopadhyay, A; Khandelwal, N; Sawhney, IM; Thussu, A, 2008) |
| "We conducted a double-blind, placebo-controlled trial in which 120 patients who had living cysticerci in the brain and seizures treated with antiepileptic drugs were randomly assigned to receive either 800 mg of albendazole per day and 6 mg of dexamethasone per day for 10 days (60 patients) or two placebos (60 patients)." | 5.11 | A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. ( Del Brutto, OH; Evans, CA; Garcia, HH; Gilman, RH; Gonzalez, AE; Herrera, G; Martinez, SM; Moulton, LH; Pretell, EJ, 2004) |
| "Albendazole plus dexamethasone increased complete or partial resolution of lesions and reduced the risk of subsequent recurrence of seizures among children with neurocysticercosis who had with seizures and 1 or 2 ring-enhancing lesions on computed tomography." | 5.10 | Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. ( Dua, T; Kalra, V; Kumar, V, 2003) |
| "In children, intracranial granuloma diagnosed on computerized tomography (CT) scan and presenting with seizures as the sole manifestation has traditionally been treated with antitubercular (ATB) therapy or albendazole (Alb) in addition to antiepileptic drugs (AED)." | 5.09 | Does treatment change the outcome of seizures and computerized tomographic lesions in intracranial granulomas? ( Kanhere, S; Mehta, R; Naik, N; Rajadhyaksha, S; Shah, KN, 1999) |
| "To evaluate the efficacy of albendazole in cases of focal seizures with SSECTLs." | 5.08 | Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial. ( Baranwal, AK; Khandelwal, N; Singhi, PD; Singhi, SC, 1998) |
| "We treated 11 patients with a persistent (> 3 months), solitary small cysticercus granuloma and seizures with albendazole in a daily dose of 15 mg/kg body weight for 14 days." | 5.07 | Albendazole therapy for persistent, solitary cysticercus granulomas in patients with seizures. ( Rajshekhar, V, 1993) |
| "Anthelminthic treatment with albendazole provides improved rates of seizure freedom and hastens resolution of the granuloma." | 4.89 | Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. ( Otte, WM; Sander, JW; Singh, G; Singla, M, 2013) |
| "A recent trial suggested that albendazole reduces seizures in adults with neurocysticercosis." | 4.84 | Does albendazole affect seizure remission and computed tomography response in children with neurocysticercosis? A Systematic review and meta-analysis. ( Mazumdar, M; Pandharipande, P; Poduri, A, 2007) |
| "Cyst resolution was unsatisfactory with albendazole monotherapy but was very high when it was followed by a combination of albendazole and praziquantel." | 4.31 | Efficacy and safety of antiparasitic therapy for neurocysticercosis in rural Tanzania: a prospective cohort study. ( Bottieau, E; Carabin, H; Dorny, P; Fleury, A; Gabriël, S; Jackson, E; Magnussen, P; Makasi, C; Mwape, KE; Ngowi, BJ; Prazeres da Costa, C; Prodjinotho, UF; Ruether, C; Schmidt, V; Stelzle, D; Trevisan, C; Van Damme, I; Winkler, AS; Zulu, G, 2023) |
| " Carbamazepine or oxcarbazepine are best suited for seizure prophylaxis for those who present with seizures; phenytoin and levetiracetam are the other alternatives." | 4.02 | Management of Neurocysticercosis in Children: Association of Child Neurology Consensus Guidelines. ( Kadwa, RA; Kamate, M; Kannan, L; Kumar, A; Passi, GR; Sankhyan, N; Sharawat, IK; Singhi, P, 2021) |
| " Diagnosis of neurocysticercosis was confirmed by positive serology and response to albendazole therapy." | 3.78 | Neurocysticercosis in a 2-year-old boy infected at home. ( Del Brutto, OH, 2012) |
| " A 32 yr old man on treatment with Albendazole for cerebral neurocysticercosis for 10 days presented with 3 days of painful uniocular blindness." | 3.76 | Monocular blindness during therapy for cerebral neurocysticercosis. ( Asole, D; Chawla, V; Lakkas, Y; Shrivastava, M; Sundar, U; Vaidy, M, 2010) |
| " Lastly, widespread neurocysticercosis may be a concern in mass treatment programs that provide praziquantel (for managing schistosomiasis) or albendazole (for managing intestinal worms or lymphatic filariasis) because these drugs may kill cerebral cysticerci, resulting in severe adverse events." | 3.74 | Could neurocysticercosis be the cause of "onchocerciasis-associated" epileptic seizures? ( Eberhard, M; Habumogisha, P; Katabarwa, M; Lakwo, T; Richards, F, 2008) |
| "To study the incidence of adverse reactions to albendazole therapy in patients presenting with seizures and a persistent (>3 months after diagnosis), solitary cysticercus granuloma and to determine whether the occurrence of adverse reactions predicted the response of the granuloma to therapy." | 3.70 | Incidence and significance of adverse effects of albendazole therapy in patients with a persistent solitary cysticercus granuloma. ( Rajshekhar, V, 1998) |
| "Albendazole is now used for therapy of neurocysticercosis; however, duration of treatment has usually been empirically determined." | 3.67 | Short course of albendazole therapy for neurocysticercosis. ( Del Brutto, OH; Escobedo, F; Penagos, P; Sotelo, J, 1988) |
| "Patients with new-onset seizures due to SCC were imaged serially using a pre-determined MRI protocol at enrolment and after 3, 6, 12 and 24months." | 2.84 | T2 relaxometry helps prognosticate seizure outcome in patients with solitary cerebral cysticercosis. ( de Souza, A; Nalini, A; Saini, J; Thennarasu, K, 2017) |
| "Neurocysticercosis is one of the most common parasitic infections in the central nervous system in children." | 2.82 | Neurocysticercosis in Children. ( Thampratankul, L; Veeravigrom, M, 2022) |
| "Neurocysticercosis is a common cause of acquired seizure disorder in developing countries, including India." | 2.73 | Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study. ( Banerjee, M; Das, K; Mondal, GP; Mukherjee, BB; Singh, OP, 2007) |
| "Neurocysticercosis is a parasitic infection of the central nervous system by the larval stage of the pork tapeworm and is a common cause of seizures and epilepsy in endemic areas." | 2.72 | Anthelmintics for people with neurocysticercosis. ( Abba, K; Monk, EJM; Ranganathan, LN, 2021) |
| "Twenty-three patients had seizure recurrence while on antiepilepsy drugs: 36." | 2.71 | Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis. ( Jain, V; Khandelwal, N; Singhi, P, 2004) |
| "Seizures were present in 94." | 2.69 | Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. ( Khandelwal, N; Ray, M; Singhi, P; Singhi, S, 2000) |
| "Seizures are the commonest manifestation of brain parenchymal cysticercosis." | 2.55 | Controversies in the treatment of seizures associated with neurocysticercosis. ( Sharma, R; Singh, G, 2017) |
| "Neurocysticercosis is an infection of the central nervous system by the larval stage of Taenia solium." | 2.49 | Corticosteroids for neurocysticercosis: a systematic review and meta-analysis of randomized controlled trials. ( Cuello-García, CA; Pérez-Gaxiola, G; Roldán-Benítez, YM; Villarreal-Careaga, J, 2013) |
| "55%; P = 0." | 2.43 | Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. ( Coffey, CS; Del Brutto, OH; García, HH; Roos, KL, 2006) |
| "Albendazole treatment leads to a remarkable reduction in neurocysticercosis lesions throughout the body." | 1.91 | Value of whole-body MRI for the assessment of response to albendazole in disseminated neurocysticercosis: a prospective follow-up study. ( Garg, RK; Jain, A; Kumar, N; Malhotra, HS; Malhotra, KP; Pandey, S; Parihar, A; Rizvi, I; Sharma, PK; Uniyal, R; Verma, R; Wangda, K, 2023) |
| "Neurocysticercosis is a major cause of acquired epilepsy." | 1.62 | Frequency and Determinant Factors for Calcification in Neurocysticercosis. ( Arroyo, G; Bustos, JA; Del Brutto, OH; Garcia, HH; Gilman, RH; Gonzales, I; Gonzalez, AE; Nash, TE; O'Neal, SE; Pretell, EJ; Saavedra, H; Soto-Becerra, P, 2021) |
| "When she presented with further seizures 6 months later, attempts to arrange neuroimaging and specialist assessment were unsuccessful owing to restrictions on routine healthcare services during the SARS-CoV-2 nationwide lockdown." | 1.62 | Hydatid brain cyst: A delayed diagnosis in a rural setting during COVID-19. ( Brink, AJ; Da Fonseca, SP; Enslin, JMN; Nuttall, J; Opperman, CJ; Tootla, HD, 2021) |
| "Cysticercosis is a neglected tropical disease set as health priority by WHO." | 1.56 | [Disseminated cysticercosis affecting the brain, the eye and the skin on a Senegalese patient]. ( Diallo, K; Diallo, M; Dione, MAD; Diop, A; Manga, NM; Wembulua, BS, 2020) |
| "Albendazole was administered at a dose of 15 mg/kg/day in 3 cycles of 28 days each." | 1.56 | Quantitative assessment of lesion load and efficacy of 3 cycles of albendazole in disseminated cysticercosis: a prospective evaluation. ( Garg, RK; Jain, A; Kohli, N; Kumar, N; Malhotra, HS; Malhotra, KP; Pandey, S; Rizvi, I; Sharma, P; Uniyal, R; Verma, R, 2020) |
| "Outcome was evaluated in terms of seizure recurrence and resolution of lesions on neuroimaging." | 1.46 | Long-term Clinical and Radiologic Outcome in 500 Children With Parenchymal Neurocysticercosis. ( Deo, B; Khandelwal, NK; Malhi, P; Singhi, P; Suthar, R, 2017) |
| "Seizures were the most common presenting symptom in 88." | 1.46 | Time trend of neurocysticercosis in children with seizures in a tertiary hospital of western Nepal. ( Adhikari, S; B K, G; Bahadur, N; Basnet, S; Gauchan, E; Mishra, R; Rao, KS; Sathian, B; Tiwari, PK, 2017) |
| "Neurocysticercosis is a leading cause of acquired epilepsy worldwide and endemic in underdeveloped and developing regions." | 1.42 | [Neurocysticercosis]. ( Burghaus, L; Fink, GR; Gottschalk, A; Meyding-Lamadé, U; Tscherpel, C, 2015) |
| "Seizures are the primary clinical manifestation which could be acute (secondary to active lesions) or remote symptomatic (due to calcified lesions)." | 1.40 | Seizure and radiological outcomes in children with solitary cysticercous granulomas with and without albendazole therapy: a retrospective case record analysis. ( Chakrabarty, B; Gulati, S; Gupta, AK; Jain, P; Kumar, A; Pandey, RM; Sachan, D, 2014) |
| "Hydatid disease is a life-threatening parasitic infestation caused by Echinococcus granulosus." | 1.39 | Primary multiple cerebral hydatid disease: still symptomatic despite pathologically confirmed death of the cyst. ( Akcakaya, MO; Aras, Y; Aydoseli, A; Hepgul, K; Imer, M; Sencer, A; Yaka, U, 2013) |
| "Neurocysticercosis is the most common parasitic infection of the central nervous system." | 1.37 | Neurocysticercosis in Qatari patients: case reports. ( Imam, YZ; Kamel, H; Khan, FY; Shafaee, M, 2011) |
| "However, recurrence of seizures can be expected in about 15% of patients." | 1.32 | Seizure outcome in patients with a solitary cerebral cysticercus granuloma. ( Jeyaseelan, L; Rajshekhar, V, 2004) |
| "To determine the risk of seizure recurrence after a first seizure due to neurocysticercosis (NC) and to evaluate risk factors for seizure recurrence, including the influence of antihelminthic treatment." | 1.31 | Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. ( Carpio, A; Hauser, WA, 2002) |
| "About 65% of cases had recurrences at varying intervals during treatment." | 1.31 | Neurocysticercosis in children: clinical characteristics and outcome. ( Choudhury, V; Popli, VK; Saxena, A; Talukdar, B, 2002) |
| "In Japan neurocysticercosis is a rare disease." | 1.31 | [A case of neurocysticercosis presenting as focal seizure]. ( Higuchi, H; Kobayashi, N; Okada, T; Sugiyama, M; Teramoto, A; Yabe, Y, 2000) |
| "Isolated intracerebral manifestation of cystic echinococcosis is very rare." | 1.31 | [Isolated intracerebral cystic echinococcosis. Unusual presentation of a rare disease]. ( Böhmer, RH; Flügel, KA; Fuchs, HH; Lücking, MO; Nowak, DA; Schreiner, R, 2002) |
| "After medical treatment of neurocysticercosis, there is usually remission or marked improvement in the associated seizure disorder." | 1.28 | The course of seizures after treatment for cerebral cysticercosis. ( Sotelo, J; Vazquez, V, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.28) | 18.7374 |
| 1990's | 7 (8.97) | 18.2507 |
| 2000's | 31 (39.74) | 29.6817 |
| 2010's | 24 (30.77) | 24.3611 |
| 2020's | 15 (19.23) | 2.80 |
| Authors | Studies |
|---|---|
| Veeravigrom, M | 1 |
| Thampratankul, L | 1 |
| Opperman, CJ | 1 |
| Enslin, JMN | 1 |
| Nuttall, J | 1 |
| Brink, AJ | 1 |
| Da Fonseca, SP | 1 |
| Tootla, HD | 1 |
| Singh, K | 1 |
| Saini, AG | 1 |
| Khandelwal, N | 6 |
| Singhi, P | 6 |
| Wangda, K | 1 |
| Kumar, N | 2 |
| Garg, RK | 5 |
| Malhotra, HS | 3 |
| Rizvi, I | 2 |
| Uniyal, R | 2 |
| Pandey, S | 3 |
| Malhotra, KP | 2 |
| Verma, R | 4 |
| Sharma, PK | 1 |
| Parihar, A | 1 |
| Jain, A | 2 |
| Singla, A | 1 |
| Lekhwani, S | 1 |
| Vaswani, ND | 1 |
| Kaushik, JS | 2 |
| Dabla, S | 1 |
| Stelzle, D | 1 |
| Makasi, C | 1 |
| Schmidt, V | 1 |
| Trevisan, C | 1 |
| Van Damme, I | 1 |
| Ruether, C | 1 |
| Dorny, P | 1 |
| Magnussen, P | 1 |
| Zulu, G | 1 |
| Mwape, KE | 1 |
| Bottieau, E | 1 |
| Prazeres da Costa, C | 1 |
| Prodjinotho, UF | 1 |
| Carabin, H | 1 |
| Jackson, E | 1 |
| Fleury, A | 1 |
| Gabriël, S | 1 |
| Ngowi, BJ | 1 |
| Winkler, AS | 1 |
| Kleebayoon, A | 2 |
| Wiwanitkit, V | 1 |
| Nazish, S | 1 |
| Almuhanna, M | 1 |
| Olivier, CJ | 1 |
| Li, H | 1 |
| Auer, RN | 1 |
| Dixit, D | 1 |
| Kohli, N | 2 |
| Sharma, P | 1 |
| Bustos, JA | 1 |
| Arroyo, G | 1 |
| Gilman, RH | 2 |
| Soto-Becerra, P | 1 |
| Gonzales, I | 1 |
| Saavedra, H | 1 |
| Pretell, EJ | 2 |
| Nash, TE | 2 |
| O'Neal, SE | 1 |
| Del Brutto, OH | 6 |
| Gonzalez, AE | 2 |
| Garcia, HH | 7 |
| Landzberg, DR | 1 |
| Dhir, A | 1 |
| Jillella, DV | 1 |
| Wembulua, BS | 1 |
| Diallo, K | 1 |
| Diallo, M | 1 |
| Dione, MAD | 1 |
| Diop, A | 1 |
| Manga, NM | 1 |
| Monk, EJM | 1 |
| Abba, K | 1 |
| Ranganathan, LN | 1 |
| Sankhyan, N | 1 |
| Kadwa, RA | 1 |
| Kamate, M | 1 |
| Kannan, L | 1 |
| Kumar, A | 2 |
| Passi, GR | 1 |
| Sharawat, IK | 1 |
| de Souza, A | 2 |
| Nalini, A | 2 |
| Saini, J | 1 |
| Thennarasu, K | 2 |
| Rao, KS | 1 |
| Adhikari, S | 1 |
| Gauchan, E | 1 |
| Sathian, B | 1 |
| B K, G | 1 |
| Basnet, S | 1 |
| Tiwari, PK | 1 |
| Bahadur, N | 1 |
| Mishra, R | 1 |
| Singh, G | 4 |
| Sharma, R | 1 |
| Carpio, A | 4 |
| Chang, M | 1 |
| Zhang, H | 1 |
| Romo, ML | 2 |
| Jaramillo, A | 1 |
| Hauser, WA | 4 |
| Kelvin, EA | 3 |
| Yaka, U | 1 |
| Aras, Y | 1 |
| Aydoseli, A | 1 |
| Akcakaya, MO | 1 |
| Sencer, A | 1 |
| Imer, M | 1 |
| Hepgul, K | 1 |
| Gulati, S | 1 |
| Jain, P | 1 |
| Sachan, D | 1 |
| Chakrabarty, B | 1 |
| Pandey, RM | 1 |
| Gupta, AK | 1 |
| Tscherpel, C | 1 |
| Gottschalk, A | 1 |
| Meyding-Lamadé, U | 1 |
| Fink, GR | 1 |
| Burghaus, L | 1 |
| Wyka, K | 1 |
| Leslie, D | 2 |
| Andrews, H | 2 |
| Bagiella, E | 2 |
| Suthar, R | 1 |
| Deo, B | 1 |
| Malhi, P | 1 |
| Khandelwal, NK | 1 |
| Burneo, JG | 2 |
| Plener, I | 1 |
| Kaur, S | 1 |
| Singhi, S | 2 |
| Asnis, D | 1 |
| Kazakov, J | 1 |
| Toronjadze, T | 1 |
| Bern, C | 1 |
| McAuliffe, I | 1 |
| Bishop, H | 1 |
| Lee, L | 1 |
| Grossmann, R | 1 |
| Garcia, MA | 1 |
| Di John, D | 1 |
| Pittayanon, R | 1 |
| Buranasupkajorn, P | 1 |
| Snabboon, T | 1 |
| Lillie, P | 1 |
| McGann, H | 1 |
| Chaurasia, RN | 1 |
| Agarwall, A | 1 |
| Singh, MK | 2 |
| Shukla, R | 2 |
| Okome-Nkoumou, MM | 1 |
| Ondounda, M | 1 |
| Dzeing-Ella, A | 1 |
| Mounguengui, D | 1 |
| Madjinou, MI | 1 |
| Clevenbergh, P | 1 |
| Magne, C | 1 |
| Nzenze, JR | 1 |
| Sundar, U | 1 |
| Chawla, V | 1 |
| Lakkas, Y | 1 |
| Shrivastava, M | 1 |
| Asole, D | 1 |
| Vaidy, M | 1 |
| Kovoor, JM | 1 |
| Yeshraj, G | 1 |
| Siddalingaiah, HS | 1 |
| Khan, FY | 1 |
| Imam, YZ | 1 |
| Kamel, H | 1 |
| Shafaee, M | 1 |
| Ooi, WW | 1 |
| Wijemanne, S | 1 |
| Thomas, CB | 1 |
| Quezado, M | 1 |
| Brown, CR | 1 |
| Takayanagui, OM | 1 |
| Odashima, NS | 1 |
| Bonato, PS | 1 |
| Lima, JE | 1 |
| Lanchote, VL | 1 |
| Khurana, N | 1 |
| Azzopardi, L | 1 |
| Quirk, J | 1 |
| Otte, WM | 1 |
| Singla, M | 1 |
| Sander, JW | 2 |
| Cuello-García, CA | 1 |
| Roldán-Benítez, YM | 1 |
| Pérez-Gaxiola, G | 1 |
| Villarreal-Careaga, J | 1 |
| Nowak, DA | 1 |
| Lücking, MO | 1 |
| Böhmer, RH | 1 |
| Schreiner, R | 1 |
| Fuchs, HH | 1 |
| Flügel, KA | 1 |
| Talukdar, B | 1 |
| Saxena, A | 1 |
| Popli, VK | 1 |
| Choudhury, V | 1 |
| Narula, G | 1 |
| Bawa, KS | 1 |
| Kalra, V | 1 |
| Dua, T | 1 |
| Kumar, V | 1 |
| Maguire, JH | 1 |
| Martinez, SM | 1 |
| Moulton, LH | 1 |
| Herrera, G | 1 |
| Evans, CA | 1 |
| Sotelo, J | 3 |
| Rojas-Flores, I | 1 |
| Kumar, S | 1 |
| Rajshekhar, V | 4 |
| Jeyaseelan, L | 1 |
| Jain, V | 1 |
| Schlaen, BR | 1 |
| Asad, S | 1 |
| Neill, MA | 1 |
| Menon, B | 1 |
| Arasu, K | 1 |
| Khairul, A | 1 |
| Waran, V | 1 |
| Roos, KL | 1 |
| Coffey, CS | 1 |
| Gonzalez, I | 1 |
| Mija, L | 1 |
| Mazumdar, M | 1 |
| Pandharipande, P | 1 |
| Poduri, A | 1 |
| Thussu, A | 1 |
| Chattopadhyay, A | 1 |
| Sawhney, IM | 1 |
| Das, K | 1 |
| Mondal, GP | 1 |
| Banerjee, M | 1 |
| Mukherjee, BB | 1 |
| Singh, OP | 1 |
| Katabarwa, M | 1 |
| Lakwo, T | 1 |
| Habumogisha, P | 1 |
| Richards, F | 1 |
| Eberhard, M | 1 |
| Leon, P | 1 |
| Chandy, MJ | 1 |
| Baranwal, AK | 1 |
| Singhi, PD | 1 |
| Singhi, SC | 1 |
| Rajadhyaksha, S | 1 |
| Shah, KN | 1 |
| Kanhere, S | 1 |
| Naik, N | 1 |
| Mehta, R | 1 |
| Sobti, P | 1 |
| Bhatia, RS | 1 |
| Singh, D | 1 |
| Ray, M | 1 |
| Sugiyama, M | 1 |
| Okada, T | 1 |
| Higuchi, H | 1 |
| Yabe, Y | 1 |
| Kobayashi, N | 1 |
| Teramoto, A | 1 |
| Vazquez, V | 1 |
| Penagos, P | 1 |
| Escobedo, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Characteristics of Patients With Symptomatic Active Neurocysticercosis and Effect of Treatment on Symptoms, Lesions and Quality of Life in Resource-poor Rural Areas of Eastern Africa - TOPANA, a Multi-centre Prospective Cohort Study.[NCT03834337] | 63 participants (Actual) | Observational | 2019-04-01 | Completed | |||
| Clinical, Laboratory and Imaging Features, Treatment Trends and Long Term Outcomes in Patients With Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study[NCT04706819] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2021-01-15 | Not yet recruiting | |||
| A Pilot Study of Neurocysticercosis Treatment[NCT00283699] | Phase 3 | 178 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for albendazole and Absence Seizure
| Article | Year |
|---|---|
Neurocysticercosis in Children.
Topics: Adolescent; Albendazole; Animals; Anticonvulsants; Antiprotozoal Agents; Blindness; Child; Child, Pr | 2022 |
Anthelmintics for people with neurocysticercosis.
Topics: Adult; Albendazole; Anticestodal Agents; Bias; Brain Diseases; Child; Humans; Neurocysticercosis; Pl | 2021 |
Antiparasitic treatment of neurocysticercosis - The effect of cyst destruction in seizure evolution.
Topics: Albendazole; Anticestodal Agents; Antiparasitic Agents; Brain; Cysts; Epilepsy; Female; Humans; Infl | 2017 |
Controversies in the treatment of seizures associated with neurocysticercosis.
Topics: Adrenal Cortex Hormones; Albendazole; Anticonvulsants; Choice Behavior; Consensus; Epilepsy; Granulo | 2017 |
Medical management of neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Brain Diseases; Humans; Life Cycle Stages; Magnetic Resonance I | 2011 |
Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis.
Topics: Adolescent; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Calcinosis; Child; Child, Preschoo | 2013 |
Corticosteroids for neurocysticercosis: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adrenal Cortex Hormones; Adult; Albendazole; Child; Drug Combinations; Humans; Magnetic Resonance Im | 2013 |
Neurocysticercosis--New Millennium, ancient disease and unending debate.
Topics: Albendazole; Animals; Anthelmintics; Anticonvulsants; Humans; Neurocysticercosis; Praziquantel; Seiz | 2003 |
Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel.
Topics: Albendazole; Anthelmintics; Humans; Neurocysticercosis; Praziquantel; Radiography; Secondary Prevent | 2006 |
Does albendazole affect seizure remission and computed tomography response in children with neurocysticercosis? A Systematic review and meta-analysis.
Topics: Albendazole; Antiparasitic Agents; Child; Child, Preschool; Databases, Factual; Humans; Neurocystice | 2007 |
20 trials available for albendazole and Absence Seizure
| Article | Year |
|---|---|
Efficacy of Combination Therapy of Albendazole and Praziquantel vs Albendazole Monotherapy in Children With Persistent Neurocysticercosis: A Randomized Controlled Trial.
Topics: Adolescent; Albendazole; Anthelmintics; Child; Child, Preschool; Drug Therapy, Combination; Humans; | 2022 |
Fourteen Days vs 28 Days of Albendazole Therapy for Neurocysticercosis in Children: An Open Label Randomized Controlled Trial.
Topics: Albendazole; Anthelmintics; Calcinosis; Child; Drug Therapy, Combination; Humans; Neurocysticercosis | 2022 |
T2 relaxometry helps prognosticate seizure outcome in patients with solitary cerebral cysticercosis.
Topics: Adolescent; Adult; Albendazole; Anticonvulsants; Brain; Child; Child, Preschool; Chronic Disease; Dr | 2017 |
Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Anthelmintics; Child; Child, Preschool; Dis | 2019 |
The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Anti-Inflammatory Agents; Brain; Cysts; Drug Therapy, Combinati | 2015 |
Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial.
Topics: Adolescent; Albendazole; Animals; Anthelmintics; Child; Child, Preschool; Double-Blind Method; Drug | 2009 |
Three day albendazole therapy in patients with a solitary cysticercus granuloma: a randomized double blind placebo controlled study.
Topics: Adolescent; Adult; Albendazole; Anticestodal Agents; Anticonvulsants; Child; Child, Preschool; Doubl | 2010 |
Perilesional gliosis around solitary cerebral parenchymal cysticerci and long-term seizure outcome: a prospective study using serial magnetization transfer imaging.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Anticonvulsants; Brain; Child; Child, Preschool; Drug | 2011 |
Three-day versus 15-day course of albendazole therapy in solitary cysticercus granuloma: an open label randomized trial.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Child; Child, Preschool; Cysticercus; Drug A | 2012 |
Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial.
Topics: Adolescent; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Anticonvulsants; Brain; Brain Edem | 2003 |
A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis.
Topics: Adolescent; Adult; Aged; Albendazole; Anti-Inflammatory Agents; Anticestodal Agents; Anticonvulsants | 2004 |
Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis.
Topics: Adolescent; Albendazole; Anticestodal Agents; Brain; Brain Diseases; Child; Child, Preschool; Drug T | 2004 |
Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Carbamazepine; Cerebral Cortex; Child; Child, Prescho | 2008 |
Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study.
Topics: Adult; Albendazole; Anthelmintics; Antiparasitic Agents; Brain; Electroencephalography; Enzyme-Linke | 2007 |
Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Albendazole; Anti-Inflammatory Agents; Antiparasitic Agents; Brain; | 2008 |
Albendazole therapy for persistent, solitary cysticercus granulomas in patients with seizures.
Topics: Adolescent; Adult; Albendazole; Animals; Brain Diseases; Cysticercosis; Cysticercus; Female; Granulo | 1993 |
Validation of diagnostic criteria for solitary cerebral cysticercus granuloma in patients presenting with seizures.
Topics: Albendazole; Anthelmintics; Brain Diseases; Clinical Protocols; Cysticercosis; Diagnosis, Differenti | 1997 |
Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial.
Topics: Adolescent; Albendazole; Animals; Anthelmintics; Brain; Child; Child, Preschool; Double-Blind Method | 1998 |
Does treatment change the outcome of seizures and computerized tomographic lesions in intracranial granulomas?
Topics: Adolescent; Albendazole; Anthelmintics; Anticonvulsants; Antitubercular Agents; Brain Diseases; Chil | 1999 |
Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy.
Topics: Albendazole; Anthelmintics; Brain Diseases; Child; Child, Preschool; Diagnosis, Differential; Female | 2000 |
48 other studies available for albendazole and Absence Seizure
| Article | Year |
|---|---|
Hydatid brain cyst: A delayed diagnosis in a rural setting during COVID-19.
Topics: Albendazole; Anticestodal Agents; Brain Diseases; Child; COVID-19; Delayed Diagnosis; Echinococcosis | 2021 |
Value of whole-body MRI for the assessment of response to albendazole in disseminated neurocysticercosis: a prospective follow-up study.
Topics: Albendazole; Anthelmintics; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Neurocysticercosi | 2023 |
Efficacy and safety of antiparasitic therapy for neurocysticercosis in rural Tanzania: a prospective cohort study.
Topics: Albendazole; Anthelmintics; Antiparasitic Agents; Cysts; Humans; Neurocysticercosis; Praziquantel; P | 2023 |
Prolonged Albendazole Therapy for Neurocysticercosis in Children.
Topics: Albendazole; Anthelmintics; Child; Humans; Neurocysticercosis; Seizures | 2023 |
Prolonged Albendazole Therapy for Neurocysticercosis in Children: Author's Reply.
Topics: Albendazole; Anthelmintics; Child; Humans; Neurocysticercosis; Seizures | 2023 |
Colloidal/Calcified
Topics: Adult; Albendazole; Hospitals; Humans; Neurocysticercosis; Saudi Arabia; Seizures | 2023 |
Disseminated alveolar echinococcosis in a 74-year-old woman presenting with focal seizure.
Topics: Aged; Albendazole; Anthelmintics; Echinococcosis; Female; Humans; Seizures | 2019 |
Quantitative assessment of lesion load and efficacy of 3 cycles of albendazole in disseminated cysticercosis: a prospective evaluation.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albendazole; Animals; Anthelmintics; Anticonvulsants; Br | 2020 |
Frequency and Determinant Factors for Calcification in Neurocysticercosis.
Topics: Albendazole; Animals; Antiparasitic Agents; Brain; Humans; Neurocysticercosis; Seizures; Taenia soli | 2021 |
Radiographic Improvement of Larval Cysts in Neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Anticonvulsants; Brain; Humans; Magnetic Resonance Imaging; Male; | 2021 |
[Disseminated cysticercosis affecting the brain, the eye and the skin on a Senegalese patient].
Topics: Aged; Albendazole; Brain; Cysticercosis; Diagnosis, Differential; Eye; Eye Infections, Parasitic; Fe | 2020 |
Management of Neurocysticercosis in Children: Association of Child Neurology Consensus Guidelines.
Topics: Albendazole; Child; Humans; Neurocysticercosis; Neurology; Phenytoin; Seizures | 2021 |
Time trend of neurocysticercosis in children with seizures in a tertiary hospital of western Nepal.
Topics: Adolescent; Albendazole; Anthelmintics; Child; Child, Preschool; Female; Follow-Up Studies; Humans; | 2017 |
Primary multiple cerebral hydatid disease: still symptomatic despite pathologically confirmed death of the cyst.
Topics: Adolescent; Albendazole; Animals; Anthelmintics; Diplopia; Echinococcosis; Echinococcus granulosus; | 2013 |
Seizure and radiological outcomes in children with solitary cysticercous granulomas with and without albendazole therapy: a retrospective case record analysis.
Topics: Albendazole; Anthelmintics; Anticonvulsants; Child; Child, Preschool; Female; Follow-Up Studies; Gra | 2014 |
[Neurocysticercosis].
Topics: Albendazole; Animals; Anthelmintics; Drug Therapy, Combination; Humans; Magnetic Resonance Imaging; | 2015 |
Long-term Clinical and Radiologic Outcome in 500 Children With Parenchymal Neurocysticercosis.
Topics: Adolescent; Albendazole; Anticestodal Agents; Child; Child, Preschool; Female; Follow-Up Studies; Hu | 2017 |
Neurocysticercosis in a patient in Canada.
Topics: Albendazole; Anti-Inflammatory Agents; Anticonvulsants; Antiprotozoal Agents; Brain; Brain Diseases; | 2009 |
Neurocysticercosis in the infant of a pregnant mother with a tapeworm.
Topics: Albendazole; Animals; Anthelmintics; Anti-Inflammatory Agents; Anticonvulsants; Carbamazepine; Dexam | 2009 |
Multiple lobulated cystic lesions in suprasellar cistern.
Topics: Adult; Albendazole; Antiparasitic Agents; Frontal Lobe; Humans; Hydrocephalus; Male; Neurocysticerco | 2009 |
Empiric albendazole therapy and new onset seizures--a cautionary note.
Topics: Adult; Albendazole; Anthelmintics; Humans; Male; Seizures | 2010 |
Epileptiform seizures revealing neurocysticercosis: report of two clinical cases in Libreville, Gabon.
Topics: Adrenal Cortex Hormones; Adult; Albendazole; Animals; Antibodies, Helminth; Anticestodal Agents; Fem | 2010 |
Monocular blindness during therapy for cerebral neurocysticercosis.
Topics: Adult; Albendazole; Anticestodal Agents; Anticonvulsants; Blindness; Brain Diseases; Dexamethasone; | 2010 |
Neurocysticercosis in Qatari patients: case reports.
Topics: Adolescent; Albendazole; Animals; Anti-Inflammatory Agents; Anticestodal Agents; Anticonvulsants; Br | 2011 |
Short report: A calcified Taenia solium granuloma associated with recurrent perilesional edema causing refractory seizures: histopathological features.
Topics: Albendazole; Animals; Anthelmintics; Anticonvulsants; Calcinosis; Edema; Granuloma; Humans; Levetira | 2011 |
An acquired source of seizures.
Topics: Adult; Albendazole; Animals; Anti-Inflammatory Agents; Anticonvulsants; Antiparasitic Agents; Develo | 2012 |
Neurocysticercosis in a 2-year-old boy infected at home.
Topics: Albendazole; Animals; Anthelmintics; Child, Preschool; Disease Transmission, Infectious; Family Heal | 2012 |
[Isolated intracerebral cystic echinococcosis. Unusual presentation of a rare disease].
Topics: Albendazole; Anthelmintics; Brain; Brain Diseases; Diagnosis, Differential; Echinococcosis; Female; | 2002 |
Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Child; Child, Prescho | 2002 |
Neurocysticercosis in children: clinical characteristics and outcome.
Topics: Adolescent; Age Distribution; Albendazole; Anticestodal Agents; Anticonvulsants; Child; Child, Presc | 2002 |
Tapeworms and seizures--treatment and prevention.
Topics: Albendazole; Animals; Anticestodal Agents; Brain Diseases; Developing Countries; Humans; Life Cycle | 2004 |
Neurocysticercosis--is the elimination of parasites beneficial?
Topics: Albendazole; Anticestodal Agents; Brain Diseases; Follow-Up Studies; Granuloma; Humans; Neurocystice | 2004 |
Anticysticercal treatment and seizures in neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Clinical Trials as Topic; Humans; Neurocysticercosis; Praziquan | 2004 |
A trial of antiparasitic treatment for cerebral cysticercosis.
Topics: Albendazole; Anti-Inflammatory Agents; Anticestodal Agents; Dexamethasone; Drug Therapy, Combination | 2004 |
A trial of antiparasitic treatment for cerebral cysticercosis.
Topics: Abdominal Pain; Albendazole; Animals; Anti-Inflammatory Agents; Anticestodal Agents; Dexamethasone; | 2004 |
Seizure outcome in patients with a solitary cerebral cysticercus granuloma.
Topics: Adolescent; Adult; Albendazole; Anticestodal Agents; Anticonvulsants; Child; Child, Preschool; Femal | 2004 |
Neurocysticercosis.
Topics: Adult; Albendazole; Animals; Anthelmintics; Humans; Magnetic Resonance Imaging; Male; Neurocysticerc | 2005 |
Starry sky and beaded legs.
Topics: Adult; Albendazole; Anticestodal Agents; Anticonvulsants; Brain; Calcinosis; Female; Headache; Human | 2006 |
Neurocysticercosis an uncommon intra-cerebral infection in Malaysia.
Topics: Adult; Albendazole; Anthelmintics; Child; Female; Humans; Magnetic Resonance Imaging; Malaysia; Male | 2005 |
Neurocysticercosis uncovered by single-dose albendazole.
Topics: Adult; Albendazole; Animals; Antiparasitic Agents; Female; Humans; Neurocysticercosis; Seizures; Tae | 2007 |
Could neurocysticercosis be the cause of "onchocerciasis-associated" epileptic seizures?
Topics: Albendazole; Animals; Anthelmintics; Epilepsy; Humans; Neurocysticercosis; Onchocerca; Onchocerciasi | 2008 |
Solitary cysticercus granulomas.
Topics: Albendazole; Animals; Brain Diseases; Cysticercosis; Granuloma; Humans; Seizures; Tomography, X-Ray | 1995 |
Incidence and significance of adverse effects of albendazole therapy in patients with a persistent solitary cysticercus granuloma.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Child; Child, Preschool; Cysticercosis; Female; Granu | 1998 |
Enlarging single CT lesions can also spontaneously resolve.
Topics: Adolescent; Albendazole; Anthelmintics; Brain; Child; Granuloma; Humans; Male; Seizures; Tomography, | 2000 |
[A case of neurocysticercosis presenting as focal seizure].
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Combined Modality Therapy; Humans; Male; Neurocys | 2000 |
Neurocysticercosis: an unusual presentation of a rare disease.
Topics: Albendazole; Anthelmintics; Calcinosis; Coma; Dexamethasone; Diagnosis, Differential; Humans; Intrac | 2002 |
The course of seizures after treatment for cerebral cysticercosis.
Topics: Adult; Albendazole; Brain; Brain Diseases; Cysticercosis; Epilepsy; Female; Follow-Up Studies; Human | 1992 |
Short course of albendazole therapy for neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Benzimidazoles; Brain; Brain Diseases; Cysticercosis; Female; Hem | 1988 |